October 20, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares over potential securities laws violations by Valeant Pharmaceuticals Intl and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) concerning whether a series of statements by Valeant Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Valeant Pharmaceuticals Intl Inc reported that its annual Total Revenue rose from over $5.76 billion in 2013 to over $8.26 billion in 2014 and that its Net Loss of $866.10 million in 2013 turned to a Net Income of $913.50 million in 2014.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) grew from $109.17 per share in August 2014 to as high as $257.53 per share in July 2015.

On October 14, 2015, post-market, Valeant disclosed that it had been subpoenaed from the U.S. Attorney's Office in Massachusetts and another from the Manhattan U.S. Attorney's Office seeking information concerning the company's pricing, drug distribution and patient assistance programs.

Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) declined to as low as $145.35 per share on October 20, 2015.